Intralesional Cemiplimab in Adult Patients with Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma: A Clinical Evaluation

The primary objective of this study is to evaluate the efficacy of **intralesional cemiplimab** in adult patients diagnosed with **cutaneous squamous cell carcinoma** or **basal cell carcinoma**. These conditions are common forms of skin cancer, and assessing the effectiveness of cemiplimab is clinically relevant as it may offer a targeted therapeutic option for patients with these malignancies. The study aims to determine the potential benefits of this treatment in reducing tumor size or progression, thereby contributing to improved patient outcomes in these specific cancer types.

The clinical trial involves a total of **108 participants** diagnosed with **Cutaneous Squamous Cell Carcinoma** and **Basal Cell Carcinoma**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet or physical activity. The sponsor has not provided information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the efficacy and safety of **intralesional cemiplimab** in adult patients diagnosed with **cutaneous squamous cell carcinoma** or **basal cell carcinoma**. This study is structured as a Phase 1 trial, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The estimated duration of the trial extends from November 2024, with the recruitment phase, to December 2025, marking the anticipated conclusion of the study.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This visit is crucial for confirming the diagnosis and ensuring that participants meet the necessary inclusion criteria. Following the initial screening, participants will attend regular follow-up visits, which are scheduled to monitor the treatment's effects and any potential adverse reactions. These visits are integral to collecting data on the primary and secondary endpoints of the trial. The end-of-study visit will occur at the conclusion of the treatment period, where final assessments will be conducted to evaluate the overall outcomes and any long-term effects of the treatment.

The expected length of participant involvement in the trial is approximately 13 months, encompassing the screening, treatment, and follow-up phases. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or withdraw consent. The trial's design and procedures are meticulously crafted to ensure the safety and well-being of participants while providing valuable insights into the potential therapeutic benefits of intralesional cemiplimab for these specific carcinomas.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of this data precludes a comprehensive description of the treatments used in the study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is November 1, 2024, with an anticipated end date of December 1, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure changes in relevant biomarkers or symptom improvement. The schedule for measuring and collecting data is typically aligned with the trial's timeline, ensuring systematic data collection at predefined intervals. The analysis of efficacy data will be conducted using appropriate statistical methods to determine the potential therapeutic effects of the investigational product. The trial's design and methodology adhere to regulatory standards to ensure the reliability and validity of the findings.